Roberta Angioni, U of Padova awarded for outstanding Bright Spark presentation at ECI meeting

MERLIN PhD student Roberta Angioni of the Università degli Studi di Padova was selected for a “Bright Spark” presentation during the 5th European Congress of Immunology (ECI). The ECI meeting was held in Amsterdam on September 2-5, 2018.

Roberta remarks: “With my great pleasure, I was awarded with the “EFIS-Biolegend Bright Sparks Award for a presentation judged outstanding” for my presentation entitled “Extracellular Vesicles derived from licensed Mesenchymal Stem Cells: a tunable approach to regulate inflammatory angiogenesis (R. Angioni, S. Herkenne, C. Liboni, R. Sanchez-Rodriguez, B. Calì, G. Borile, A. Viola, Padova, Italy)”.

Erasmus MC Mentor-Mentee team wins at Congress of the Transplantation Society

Erasmus Medical Center PhD student Jesus Sierra presented Merlin data at the Congress of the Transplantation Society in Madrid in July 2018. The title of Jesus’ talk was:  Monocytic cells phagocytose therapeutic mesenchymal stem cells, which induces polarization, relocation and immune regulation. Jesus Sierra in conjunction with Martin Hoogdujin, his mentor claimed the mentor-mentee award at the 27th International Congress of The Transplantation Society.  This year’s meeting was held in Madrid, Spain from June 30 to July 5, 2018.

Pictured below from left to right: Martin Hoogduijn, Erasmus Medical Center, Rotterdam, Marlies Reinders, President of the Dutch Transplantation Society, and Jesus Sierra, presenter and PhD student.

MERLIN publishes in Cytotherapy

The MERLIN study “Epigenetic changes in umbilical cord mesenchymal stromal cells upon stimulation and culture expansion” has been recently published in Cytotherapy The Journal of Cell Therapy. The body of research by Samantha F.H. de Witte1, Fleur S. Peters1, Ana Merino1, Sander S. Korevaar1, Joyce B.J. van Meurs2, Lisa O’Flynn3, Steve J. Elliman3, Philip N. Newsome46, Karin Boer1, Carla C. Baan1 and Martin J. Hoogduijnwas accepted for publication on May 8, 2018. Cytotherapy is the Official Journal of the International Society for Cellular Therapy (ISCT)

Abstract: Mesenchymal stromal cells (MSCs) are studied for their immunotherapeutic potential. Prior to therapeutic use, MSCs are culture expanded to obtain the required cell numbers and, to improve their efficacy, MSCs may be primed in vitro. Culture expansion and priming induce phenotypical and functional changes in MSCs and thus standardisation and quality control measurements come in need. We investigated the impact of priming and culturing on MSC DNA methylation and examined the use of epigenetic profiling as a quality control tool.

Read about the roles of the partner organizations within MERLIN here.

doi: https://doi.org/10.1016/j.jcyt.2018.05.005 [Epub ahead of print]

Published on June 19, 2018.

Find the link to the paper here.

1Nephrology and Transplantation, 2Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands; 3Orbsen Therapeutics Ltd., Galway, Ireland; 4National Institute for Health Research Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. 5Centre for Liver Research, Institute of Immunology and Immunotherapy, University of Birmingham. 6Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

 

MERLIN trial attracts attention at Bioprocessing and Advanced Cellular Therapies Congress 2018

 

Head of Process Development at Orbsen Therapeutics, Limited, Dr Lisa O’ Flynn attended the 3rd Annual Bioprocessing and Advanced Cellular Therapies Congress in Frankfurt, Germany. The meeting was held on the 29th-30th of May 2018. Lisa gave an oral presentation entitled ” CD362 to ORBCEL: the rapid development of a novel stromal cell therapy ” wherein the MERLIN clinical trial was highlighted.

Roberta Angioni, University of Padua presents MERLIN at the Pediatric Research Institute meeting

Roberta Angioni of the Department of Biomedical Science at the University of Padua presented MERLIN’s objectives and results during  an invited talk entitled “Mesenchymal stem cells and their extracellular vesicles in the control of pathological angiogenesis” at the Pediatric Research Institute (IRP) meeting held April 7, 2018, at the Villa Pace Park Hotel, Preganziol in Treviso, Italy. Roberta Angioni is a PhD candidate under the supervision of Prof Antonella Viola at the University of Padua.

Read about the University of Padua’s role within MERLIN here.

 

Immunomodulation By Therapeutic MSC Is Triggered Through Phagocytosis of MSC By Monocytic Cells

A new MERLIN publication led by our team at Erasmus MC in Rotterdam, NL appeared in the journal Stem Cells on 17 January 2018. Authors of this paper are: Samantha F H de Witte , Franka Luk, Jesus M Sierra Parraga, Madhu Gargesha, Ana Merino, Sander S Korevaar, Anusha S Shankar, Lisa O’Flynn, Steve J Elliman, Debashish Roy , Michiel G H Betjes, Philip N Newsome, Carla C Baan, Martin J Hoogduijn.

This important study demonstrates that infused MSC are rapidly phagocytosed by monocytes, which subsequently migrate from the lungs to other body sites. Phagocytosis of ucMSC induces phenotypical and functional changes in monocytes, which subsequently modulate cells of the adaptive immune system. It can be concluded that monocytes play a crucial role in mediating, distributing, and transferring the immunomodulatory effect of MSC.

Visit our Publications page for more information on this and other MERLIN publications.

 

Merlin Newsletter Winter 2017 – 2018

The Merlin Newsletter for Winter 2017 – 2018 has just been issued! This is the second edition of our newsletter and includes the following sections:

  • Refresher Course – a reminder of the project’s key aims and objectives
  • Forging Ahead – a brief update on recent progress
  • Read All About it – details of some of our recent publications
  • Out and About – recent presentations made and events attended by the team.
  • Merlin Materials – helpful resources you can use to find out more about the Project
  • Meet the Team – the partners behind the project

You can access the Newsletter here.

Merlin team meet in Padua

The Merlin partners met in Padua on 22 and 23 January for our most recent plenary. The team heard updates from workstreams across the project and discussed the reports to be submitted to the EU by the end of January. MSC manufacture and plans for the clinical trial were also a key focus. An exploitation workshop was held where future exploitation plans were considered. Many thanks to UNIPD for hosting such a successful meeting in such a wonderful location!

 

S. de Witte, Erasmus MC presents MERLIN findings in 2017

S. de Witte of Erasmus University Medical Center in Rotterdam took to the road in 2017 to present MERLIN results at five conferences in Belgium, The Netherlands and Spain:

· Erasmus MC, Science days of the Department of Internal Medicine, Antwerp
Poster: IMPACT OF CULTURE EXPANSION AND INFLAMMATORY CYTOKINE CHALLENGE ON DNA METHYLATION PROFILES IN MSC

· BOOT conference, Dutch Transplantation Society, Groningen
Presentation 1: Ageing of bone marrow and umbilical cord-derived MSC during culture expansion
Presentation 2: In vivo tracking of live and dead mesenchymal stromal cells

· MOLMED day, Erasmus MC molecular medicine, Rotterdam
Poster: IMPACT OF CULTURE EXPANSION AND INFLAMMATORY CYTOKINE CHALLENGE ON DNA METHYLATION PROFILES IN MSC

· European Society for Organ Transplantation (ESOT), Barcelona
Presentation 1: Impact of culture expansion and inflammatory cytokine challenge on DNA methylation profiles in MSC
Presentation 2: Tracking and fate of umbilical cord-derived MSC after intravenous infusion in mice (presented by F. Luk)

· European Hematology Association (EHA), EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy, Amsterdam
Presentation: Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells

After six conference talks and poster presentations, she remarked, ”It was nice to connect with the experts in the field”.

MERLIN will present at EU-MSC2 meeting in Leiden in September

Hosted by Leiden University Medical Center, the EU MSC2 2017 meeting in Leiden, NL on September 12th and 13th will assemble twelve EU-funded, mesenchymal stromal cell-focussed consortia. Projects to be presented include: REDDSTARREACHRETHRIM, Stellar, MERLINNephstromSCIENCEVISICORT and Adipoa-2AUTOSTEMBOOSTB4, SEPCELL, RESSTORE, and RESPINE. This two day, interactive meeting will be held at the Stadsgehoorzaal Leiden. Three overarching aspects of the EU-MSC2 meeting include: mechanisms of action and potency assays; an interactive panel discussion on product development, and product development and market authorisation in a changing regulatory landscape.

The objectives of the meeting are to:

  • Enhance knowledge-sharing between EU research groups working in the mesenchymal stromal cell biology domain
  • Engage with European Commission Project Officers and other stakeholders from International Society of Cellular Therapy, stem cell ethicists and the European Medicines Agency (EMA)
  • Assemble trans-disciplinary research groups working across the global health spectrum but with a common focus of mesenchymal stromal cell biology
  • Bring up-and-coming researchers together for networking purposes, and to explore future consortium building and international funding application opportunities

Expected impacts and outcomes:

  • Provide opportunities to develop new mesenchymal stromal cell networks
  • Disseminate the findings and challenges between MSC-focussed consortia
  • Improve the communication potential of research, outcomes and the value of the research
  • Explore potential for new commercial technologies
  • Collectively enhance the quality and impact of planned clinical trials

These EU-funded projects are:

  • Improving the quality of life for European citizens
  • Progressing the clinical translation of MSC research and developments

For more information, please visit EU MSC2 2017.
Register via Eventbrite by August 14 2017.
Read the EU-MSC2 2015 meeting report here.